Literature DB >> 18573766

Evidence-informed evidence-making.

Kalipso Chalkidou1, Tom Walley, Anthony Culyer, Peter Littlejohns, Andrew Hoy.   

Abstract

The extent to which clinical and public health guidance developed by the National Institute for Health and Clinical Excellence (NICE) can effectively serve the public by improving quality and efficiency across the National Health Service (NHS) and the broader public sector depends largely on the quality and relevance of the available evidence which informs its decisions. There are well-established organizational and procedural links between NICE and academic and professional organizations that undertake evidence synthesis. However, there are fewer means for evidence gaps identified during the development of NICE guidance to lead to the commissioning of new prospective studies. In this paper, we discuss the importance of a publicly funded clinical and public health research agenda that includes new prospective studies aimed at addressing knowledge gaps identified by NICE. We describe the early experience of NICE and the National Institute for Health Research (NIHR) working together to articulate and commission research to inform best practice recommendations. We propose ways in which NICE can collaborate more effectively with research funders to improve the evidence base upon which it bases its recommendations.

Mesh:

Year:  2008        PMID: 18573766     DOI: 10.1258/jhsrp.2008.008027

Source DB:  PubMed          Journal:  J Health Serv Res Policy        ISSN: 1355-8196


  7 in total

Review 1.  Validity of British Thoracic Society guidance (the CRB-65 rule) for predicting the severity of pneumonia in general practice: systematic review and meta-analysis.

Authors:  Maggie McNally; James Curtain; Kirsty K O'Brien; Borislav D Dimitrov; Tom Fahey
Journal:  Br J Gen Pract       Date:  2010-10       Impact factor: 5.386

2.  Comparative effectiveness research and evidence-based health policy: experience from four countries.

Authors:  Kalipso Chalkidou; Sean Tunis; Ruth Lopert; Lise Rochaix; Peter T Sawicki; Mona Nasser; Bertrand Xerri
Journal:  Milbank Q       Date:  2009-06       Impact factor: 4.911

3.  Real world partnership with patients.

Authors:  Josie Solomon; Ruth Shelton; Sandy Taylor
Journal:  Br J Gen Pract       Date:  2019-09-26       Impact factor: 5.386

4.  Efficacy of Jian'ganle () versus Hugan Pian (), glucuronolactone and reduced glutathione in prevention of antituberculosis drug-induced liver injury.

Authors:  Quan Zhang; Fang-Ying Zhong; Meng Wu; Xin-Ping Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-06-18

5.  Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.

Authors:  N Maniadakis; G Kourlaba; J Shen; A Holtorf
Journal:  BMC Health Serv Res       Date:  2017-05-25       Impact factor: 2.655

6.  Using HTA and guideline development as a tool for research priority setting the NICE way: reducing research waste by identifying the right research to fund.

Authors:  Tarang Sharma; Moni Choudhury; Juan Carlos Rejón-Parrilla; Pall Jonsson; Sarah Garner
Journal:  BMJ Open       Date:  2018-03-08       Impact factor: 2.692

Review 7.  When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance.

Authors:  Louise Longworth; Jihee Youn; Laura Bojke; Stephen Palmer; Susan Griffin; Eldon Spackman; Karl Claxton
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.